Captivate Bio expands cell culture media focus and small molecule kits for stem cell research and emerging markets

  • Additional cell culture media products will support fast growing research markets
  • New kit sets the standard for minimizing cellular stress and enhancing stem cell survival

WATERTOWN, Mass.--(BUSINESS WIRE)-- Captivate Bio, a scientific solutions provider, announced that it has expanded its portfolio of cell culture solutions to include new classical media along with custom media manufacturing services and its new CET Cocktail, a kit of small molecule compounds that can be safely used in research and regenerative medicine applications to greatly improve the human pluripotent stem cell (hPSC) workflow.

This expanded offering focuses on addressing supply gaps created by recent mergers and acquisitions of large biotech corporations, which have left researchers with increasingly limited options for reliable reagent manufacturing and supply. Captivate Bio’s custom media and procurement services will give researchers and industry partners additional options for sourcing high-quality cell culture reagents and defined media solutions, as well as provide bulk supply and custom media formulations.

Captivate Bio’s CET Cocktail complements its stem cell reagent portfolio with a key small molecule kit supporting the media supplement strategy known as CEPT (Chroman 1, Emricasan, Polyamine solution, and Trans-ISRIB). CEPT is a newly published, optimized combination of targeted small molecules and culture additives shown to overcome cellular stressors inherent in stem cell workflows and address the key challenges in translational stem cell research. The CET Cocktail offers a significant improvement in stem cell viability, clonality, expansion, and cryopreservation, enabling researchers to reliably generate large numbers of safe and consistent cell banks applicable for downstream therapeutic use.

“The demand for readily available cell culture systems continues to increase with the growth of translational research and emerging technologies,” said Tanya Potcova, Co-founder and CEO, Captivate Bio. “Our mission is to not only supplement media manufacturing here in the US, but to make custom media formulations more accessible and cost-effective for scientists at all levels. Both the CET Cocktail and our custom media services align with Captivate Bio’s goal of delivering value that advances our customers' research while increasing worldwide access to new technologies."

Captivate Bio will showcase its new offerings at the BTCI Wisconsin Stem Cell Symposium, held on April 20, 2022, in Madison, Wisconsin.

About Captivate Bio
Based in Watertown, MA, Captivate Bio is a privately held scientific solutions provider specializing in the commercialization and distribution of high-quality reagents and custom cell culture media services for the research, therapeutic, and healthcare communities. Current product offering includes classical cell culture media, specialty media, animal sera including FBS, small molecules, biomatrices, human platelet lysate, and custom media manufacturing services for basic research, stem cell research, cell therapy, and emerging markets, such as cellular agriculture.

For more information, visit www.captivatebio.com or follow-on LinkedIn, Facebook, Instagram, and Twitter.

Source: Captivate Bio

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.